In a cohort study of 785 patients with pancreatic ductal adenocarcinoma, the presence of mutant KRAS circulating tumor DNA (ctDNA) was linked to higher metastatic risk and poorer survival outcomes. Out of those tested, 104 showed plasma MKRAS positivity, correlating with increased likelihood of metastatic disease. Furthermore, among 419 patients tested for peritoneal MKRAS, 123 were positive, revealing a tendency towards occult metastases. Overall, MKRAS detection significantly impacts prognosis and treatment strategies in localized PDAC cases.
Journal Article by Leiting JL, Alva-Ruiz R (…) Truty MJ et 15 al. in Ann Surg Oncol
© 2025. The Author(s).